Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Belite Bio in a research note issued to investors on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.37) for the quarter, down from their previous forecast of ($0.32). HC Wainwright currently has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Belite Bio (NASDAQ:BLTE) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

A number of other research analysts have also commented on BLTE. Benchmark boosted their price target on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Belite Bio in a research report on Tuesday.

Belite Bio Trading Down 0.7 %

Belite Bio stock opened at $67.28 on Thursday. Belite Bio has a 1-year low of $31.01 and a 1-year high of $86.53. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of -60.61 and a beta of -1.54. The firm has a 50 day simple moving average of $59.48 and a 200 day simple moving average of $60.84.

Institutional Trading of Belite Bio

Several hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its stake in Belite Bio by 28.2% in the third quarter. State Street Corp now owns 20,086 shares of the company’s stock worth $942,000 after purchasing an additional 4,415 shares during the last quarter. Bank of America Corp DE lifted its stake in Belite Bio by 36.4% in the fourth quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after purchasing an additional 4,891 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Belite Bio by 130.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,636 shares of the company’s stock worth $924,000 after purchasing an additional 8,280 shares during the last quarter. XTX Topco Ltd lifted its stake in Belite Bio by 30.9% in the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock worth $446,000 after purchasing an additional 1,668 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in Belite Bio in the fourth quarter worth $155,000. 0.53% of the stock is owned by institutional investors.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.